Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.33 -0.75%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- CrowdStrike (CRWD) PT Adjusted $250 at Cantor Fitzgerald Post Stock Split
- Exyn Technologies, Inc. (EXYN) Reports Q2 Loss of $1.55
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
